Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Jason Coloma Sells 34,501 Shares

Key Points

• CEO Jason Coloma sold 34,501 Maze Therapeutics shares at an average price of $27.02, generating approximately $932,217. The Rule 10b5-1 transaction reduced his direct stake by 68.92% to 15,558 shares.
• MAZE shares traded near $26.43, with a market capitalization of approximately $1.47 billion. The company reported a quarterly loss of $0.76 per share, in line with analyst expectations.
• Analyst sentiment remains broadly positive, with an overall “Buy” rating and an average price target of $63.40, although ratings range from “Strong Buy” to “Sell.”

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CEO Jason Coloma sold 34,501 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $27.02, for a total value of $932,217.02. Following the completion of the transaction, the chief executive officer directly owned 15,558 shares in the company, valued at approximately $420,377.16. This represents a 68.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

MAZE stock traded down $0.22 during mid-day trading on Friday, hitting $26.43. 633,043 shares of the stock were exchanged, compared to its average volume of 665,641. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The business has a fifty day moving average price of $27.00 and a 200 day moving average price of $28.23. Maze Therapeutics, Inc. has a 12 month low of $21.95 and a 12 month high of $53.65. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -10.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). On average, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $48,000. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company's stock valued at $61,000 after buying an additional 1,383 shares during the period. Quantbot Technologies LP purchased a new position in shares of Maze Therapeutics during the second quarter valued at approximately $80,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics during the fourth quarter valued at approximately $145,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Maze Therapeutics during the second quarter valued at approximately $200,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. BTIG Research reaffirmed a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Monday, September 21st. HC Wainwright reiterated a "buy" rating and issued a $110.00 price objective on shares of Maze Therapeutics in a report on Thursday, September 24th. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $63.40.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.